NAN warns health care practitioners about dangers posed by EPHINEPHrine shortage

NewsGuard 100/100 Score

A National Alert for Serious Medication Errors (NAN) was issued yesterday by the American Society of Health-System Pharmacists (ASHP) and the Institute for Safe Medication Practices (ISMP), warning health care practitioners about dangerous medication errors that could be caused by a shortage of EPINEPHrine pre-filled syringes.

The alert was prepared as a caution to health care organizations and practitioners even though there had been no reports of deaths or serious errors at that time. However, days before the alert was finalized, news media in Bangor, Maine, reported the death of a hospital patient from an overdose of EPHINEPHrine. It is unknown at this time whether the EPHINEPHrine shortage was a factor in the deadly error.

The NAN warns health care practitioners about dangers posed by this drug shortage and includes recommendations to prevent medication errors that could result from the shortage.

The NAN was developed by the American Society of Health-System Pharmacists and the Institute for Safe Medication Practices to help bring an end to deadly medication errors. Physicians, pharmacists, and nurses are expected to use the recommendations to take immediate action to prevent serious medication errors at their facility.

Alerts are issued by ASHP and ISMP only when a significant risk for serious or fatal errors is detected through ISMP's Medication Error Reporting Program (MERP) and the alert is distributed by the National Council on Medication Error Reporting and Prevention.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
The International Eczema Council investigate how climate change may impact eczema